LON:VLG - Venture Life Group Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 93.09
▲ +0.093 (0.10%)

This chart shows the closing price for VLG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Venture Life Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VLG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VLG

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Venture Life Group in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 93.09.

This chart shows the closing price for VLG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Venture Life Group. This rating has held steady since November 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2018Northland SecuritiesReiterated RatingBuy
9/20/2018Northland SecuritiesReiterated RatingBuy
8/16/2018Northland SecuritiesReiterated RatingBuy
8/2/2018Northland SecuritiesReiterated RatingBuy
7/20/2018Northland SecuritiesReiterated RatingBuy
6/18/2018Northern Trust Capital MarketsReiterated RatingBuyGBX 100
6/18/2018Northland SecuritiesReiterated RatingBuy
6/4/2018Northland SecuritiesReiterated RatingBuy
5/21/2018Northland SecuritiesReiterated RatingBuy
5/9/2018Northland SecuritiesReiterated RatingBuyGBX 100
3/22/2018Northland SecuritiesBoost Price TargetBuyGBX 94 ➝ GBX 100
2/20/2018Northland SecuritiesReiterated RatingBuyGBX 94
2/13/2018Northland SecuritiesReiterated RatingBuyGBX 94
1/31/2018Northland SecuritiesReiterated RatingBuyGBX 94
1/8/2018Northland SecuritiesReiterated RatingBuyGBX 94
11/24/2017Northland SecuritiesReiterated RatingBuyGBX 94
10/30/2017Northland SecuritiesReiterated RatingBuyGBX 94
10/2/2017Northland SecuritiesInitiated CoverageBuyGBX 94
9/22/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
9/21/2017Northland SecuritiesReiterated RatingCorporate
9/8/2017Northland SecuritiesReiterated RatingCorporate
9/8/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
7/19/2017Northland SecuritiesReiterated RatingCorporate
7/12/2017Northland SecuritiesReiterated RatingCorporate
5/18/2017Northland SecuritiesReiterated RatingCorporate
5/4/2017Northland SecuritiesReiterated RatingCorporate
4/20/2017Panmure GordonReiterated RatingBuyGBX 128
3/23/2017Panmure GordonReiterated RatingBuyGBX 128
1/26/2017Panmure GordonReiterated RatingBuyGBX 128
11/15/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
11/14/2016Panmure GordonReiterated RatingBuyGBX 128
10/10/2016Panmure GordonReiterated RatingBuyGBX 128
9/22/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
9/21/2016Panmure GordonReiterated RatingBuyGBX 128
8/1/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
7/29/2016Panmure GordonReiterated RatingBuyGBX 128
(Data available from 7/25/2016 forward)
Venture Life Group logo
Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, dermo-cosmetics, and topical products for the ageing population in the United Kingdom, Netherlands, China, Germany, Italy, Switzerland, rest of Europe, and internationally. It operates through Venture Life Brands and Customer Brands segments. The company offers neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance mental alertness, cognitive function, and mental performance in ageing brain; and Original Bioscalin to treat and prevent hair loss, hair thinning, and baldness. It also provides Fungal Nail Solution, which helps to treat and prevent fungal infections; and Fungal Nail Cleanser for the hygiene of hands and feet prone to fungal nail infections under the Myco Clear brand name. In addition, the company offers UltraDEX Original and UltraDEX Sensitive for bad breath; Dently Dual Action, a mouthwash, which lifts and removes plaque and bacteria from the teeth and mouth; and Procto-eze for anal irritation, including haemorrhoids condition. Further, it provides women healthcare products comprising vonalei bacterial vaginosis, a refreshing gel; vonalei Vaginal Atrophy, a vaginal cream; vonalei candidiasis, a soothing cream-gel for thrush; and vonalei intimate cleansing foam. Additionally, it offers Cleansing Foam, Cleansing Cream, and Serum under the Rosa calma brand name; and skincare ranges to hydrate, nourish, and recondition the skin, as well as to prevent the lines and wrinkles under the Lubatti Classic and the Lubatti Anti-age brand names. The company sells its products through a network of international partners, retail pharmacies, as well as grocery multiple retailers. Venture Life Group plc was incorporated in 2005 and is headquartered in Bracknell, the United Kingdom.
Read More

Today's Range

Now: GBX 93.09
Low: 92.90
High: 95

50 Day Range

MA: GBX 92.37
Low: 84
High: 103

52 Week Range

Now: GBX 93.09
Low: 75.10
High: 118

Volume

921,880 shs

Average Volume

241,611 shs

Market Capitalization

£117.14 million

P/E Ratio

37.24

Dividend Yield

0.09%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Venture Life Group?

The following Wall Street analysts have issued stock ratings on Venture Life Group in the last year:
View the latest analyst ratings for VLG.

What is the current price target for Venture Life Group?

0 Wall Street analysts have set twelve-month price targets for Venture Life Group in the last year. has the lowest price target set, forecasting a price of £100,000 for Venture Life Group in the next year.
View the latest price targets for VLG.

What is the current consensus analyst rating for Venture Life Group?

Venture Life Group currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VLG.

What other companies compete with Venture Life Group?

How do I contact Venture Life Group's investor relations team?

Venture Life Group's physical mailing address is Venture House 2 Arlington Square, Downshire Way, BRACKNELL, RG12 1WA, United Kingdom. The company's listed phone number is +44-1344-742870. The official website for Venture Life Group is www.venture-life.com.